Table 3. 5-year and 10-year cumulative CSS and OS of patients with different clinicopathological features.
| Cancer-specific survival | Overall survival | |||||
|---|---|---|---|---|---|---|
| 5-year | 10-year | Log-rank Test, P | 5-year | 10-year | Log-rank Test, P | |
| Age group | ||||||
| <50 | 95.97 | 93.01 | NS | 95.4 | 90.8 | <0.001 |
| 50–69 | 98.13 | 96.47 | 95.69 | 88.86 | ||
| > = 70 | 95.69 | 95.69 | 78.87 | 69.5 | ||
| County type 2003* | ||||||
| Metropolitan | 96.89 | 95.46 | NS | 94.24 | 88.65 | NS |
| Non-metropolitan | 96.97 | 90.93 | 93.1 | 82.86 | ||
| Race* | ||||||
| White | 97.63 | 95.18 | 0.003 | 95.08 | 88.38 | 0.01 |
| African American | 88.54 | 88.54 | 82.94 | 79.48 | ||
| Others | 100 | 100 | 98.48 | 94.55 | ||
| Marital status* | ||||||
| Married | 97.46 | 94.92 | NS | 96.03 | 91.23 | 0.002 |
| Divorced | 95.66 | 94.33 | 90.35 | 82.33 | ||
| Primary Site | ||||||
| Nipple/Central portion | 100 | 88.89 | NS | 94.59 | 84.08 | NS |
| UIQ | 98.57 | 95.39 | 97.14 | 94.01 | ||
| LIQ | 94.5 | 94.5 | 94.5 | 94.5 | ||
| UOQ | 97.24 | 94.46 | 94.96 | 88.62 | ||
| LOQ | 100 | 94.44 | 91.52 | 86.43 | ||
| OVERLAPPING/UNKNOWN | 95.18 | 95.18 | 92.67 | 86.47 | ||
| NOS | 96.62 | 96.62 | 93.82 | 87.42 | ||
| T-stage | ||||||
| Tis | 99.6 | 99.6 | <0.001 | 97.9 | 93.1 | <0.001 |
| T1 | 97.81 | 94.95 | 96.11 | 89.6 | ||
| T2 | 90.49 | 85.18 | 84.92 | 75.87 | ||
| T3 | 91.64 | 83.31 | 84.28 | 76.62 | ||
| N-stage | ||||||
| N0 | 98.63 | 97.44 | <0.001 | 95.68 | 90.98 | <0.001 |
| N1 | 89.76 | 81.28 | 88.96 | 72.71 | ||
| N2 | 90.34 | 90.34 | 86.04 | 76.48 | ||
| N3 | 75 | 75 | 68.18 | 68.18 | ||
| Histology | ||||||
| In situ carcinoma | 99.6 | 99.6 | <0.001 | 97.9 | 93.1 | 0.005 |
| IDC | 93.94 | 91.26 | 91.51 | 87.76 | ||
| ILC | 97.5 | 82.03 | 95.73 | 69.73 | ||
| Others | 97.88 | 95.93 | 90.64 | 82.23 | ||
| Grade | ||||||
| I | 100 | 98.36 | NS | 95.61 | 89.96 | NS |
| II | 97.24 | 93.66 | 94.9 | 86.44 | ||
| III | 93.99 | 92.67 | 92.17 | 88.75 | ||
| IV | 97.06 | 97.06 | 92.14 | 83.32 | ||
| Unknown | 97.94 | 96.65 | 94.78 | 90.57 | ||
| ER | ||||||
| Negative | 92.39 | 92.39 | NS | 90.14 | 90.14 | NS |
| Positive | 97.29 | 94.5 | 94.57 | 88.24 | ||
| Unknown | 97.7 | 96.64 | 94.3 | 87.58 | ||
| PR | ||||||
| Negative | 94.27 | 93 | NS | 93.54 | 86.26 | NS |
| Positive | 97.02 | 94.17 | 93.58 | 89.11 | ||
| Unknown | 97.95 | 96.91 | 94.9 | 88.32 | ||
| Radiation therapy | ||||||
| No | 97.79 | 96.2 | <0.001 | 94.87 | 89.62 | 0.013 |
| Yes | 95.49 | 92.95 | 92.85 | 83.87 | ||
| Unknown | 82.25 | 65.8 | 82.25 | 65.8 | ||
ER, estrogen receptor; PR, progesterone receptor; LIQ, lower-inner quadrant; LOQ, lower-outer quadrant; UIQ, Upper-inner quadrant; UOQ, Upper-outer quadrant; NOS, Non otherwise specified.IDC, infiltrating ductal carcinoma; ILC, Invasive lobular carcinoma. NS, Non-significant; CSS, Cancer-specific survival; OS, Overall survival;
* Patients with unknown status were excluded. Separated/Single/Widowed were included in the divorce category.